Q1 FY27 loss at Amerise Biosciences amid zero revenue

Net loss reportedRevenue declinedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.2%Reaction day

₹0.96

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-4.6% vs market

Plastic Products - Industrial peers, median of 36sector-0.7%-3.5% vs sector

On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 3.5 pts less than its Plastic Products - Industrial peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.2+0.4-4.6-0.7-3.5

Next day

-8.3+1.7-10.1-0.7-7.6

-7.3+2.1-9.4+0.0-7.3

-5.2+2.1-7.3-0.9-4.3

-10.4+2.1-12.5-1.4-9.1

-10.4+1.9-12.3-1.5-8.9

-11.5+2.4-13.9-1.1-10.4

15d

-13.5+3.0-16.6-1.2-12.3

-10.4+3.7-14.1+0.1-10.5

-17.7+1.6-19.3-3.7-14.0

—————

UpDownMarket · Nifty Microcap 250Sector · Plastic Products - Industrial peers, median of 36Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Amerise Biosciences (formerly Amradeep Industries) posted nil revenue from operations in Q1 FY27 (quarter ended 30 June 2026) and a net loss of Rs 8.14 lacs, against a profit of Rs 6.13 lacs on Rs 7.92 lacs revenue in Q4 FY26. Total expenses stood at Rs 8.14 lacs. FY26 ended with negative other equity of Rs 121.10 lacs. The auditor issued an unqualified limited review.

Likely market impact

Zero revenue and losses continue; negative reserves signal financial stress for this small-cap.